Effects of Omega‐3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue
Authors:
- 22 December 2017
- journal article
- research article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 22 (2) , 124-132
Abstract
Chronic kidney disease (CKD) is a global problem which contributes to a significant morbidity and mortality in China. Concomitant inflammatory state further boosts the mortality due to cardiovascular events in patients with CKD undergoing dialysis. There is a general notion that Omega‐3 fatty acids including docosahexaenoic acids (DHA) and eicosapentaenoic (EPA) have certain health benefits perhaps via the regulation of inflammation. However, the anti‐inflammatory effect of omega‐3 fatty acids in patients with CKD is controversial. We analyzed the data of oral supplementation of omega‐3 fatty acids in CKD patients by searching literature on database from inception to August 2016. The analysis included randomized controlled trials (RCTs) derived from multiple databases, and the effect of omega‐3 fatty acids supplementation versus the control cohorts were compared. All of the data analysis was calculated by RevMan 5.2. A total of 12 RCTs involving 487 patients were included in the meta‐analysis. Among them 254 patients received omega‐3 fatty acids and 233 patients served as controls who received placebo. The meta‐analysis revealed no statistical significance in serum levels of C‐reactive protein (CRP) (SMD, −0.20; 95% CI, −0.44 to 0.05; P = 0.11), IL‐6 (SMD, 0.00; 95% CI, −0.33 to 0.33; P = 0.99) and TNF‐α (SMD, 0.14; 95% CI, −0.17 to 0.44; P = 0.38) between the omega‐3 fatty acids supplementation group and control. This suggested that there is insufficient evidence to conclude the benefit of omega‐3 fatty acids oral supplementation in reducing serum levels of CRP, IL‐6 and TNF‐α in patients with CKD.Keywords
Funding Information
- National Institutes of Health (DK60635)
This publication has 67 references indexed in Scilit:
- Cardioprotective Effects ofω-3 PUFAs in Chronic Kidney DiseaseBioMed Research International, 2013
- Omega-3 Polyunsaturated Fatty Acids Antagonize Macrophage Inflammation via Activation of AMPK/SIRT1 PathwayPLOS ONE, 2012
- Biomarkers of Chronic Inflammatory State in Uremia and Cardiovascular DiseaseInternational Journal of Inflammation, 2012
- Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patientsVascular Health and Risk Management, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- n–3 Fatty Acids in Cardiovascular DiseaseNew England Journal of Medicine, 2011
- Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Elevated circulating levels of interleukin-6 in patients with chronic renal failureKidney International, 1991